AstraZeneca's Imfinzi gets EU approval for Stage III NSCLC

TL;DR

EU approves AstraZeneca's Imfinzi for Stage III lung cancer, expanding market reach.

AI Summary

AstraZeneca PLC announced on July 7, 2025, that its Imfinzi drug has received approval in the European Union for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have received prior chemoradiotherapy. This approval is based on the positive results from the PACIFIC Phase III trial.

Why It Matters

This EU approval expands the treatment options for patients with unresectable Stage III NSCLC, potentially improving outcomes for a significant patient population in Europe.

Risk Assessment

Risk Level: low — This is a routine regulatory filing announcing an existing drug approval, with no new financial or operational risks disclosed.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant and drug manufacturer
• Imfinzi (drug) — Approved medication
• European Union (geography) — Region of approval
• Stage III non-small cell lung cancer (NSCLC) (medical_condition) — Indication for drug approval
• PACIFIC Phase III trial (clinical_trial) — Basis for approval

FAQ

From the Filing

0001654954-25-007785.txt : 20250707 0001654954-25-007785.hdr.sgml : 20250707 20250707062413 ACCESSION NUMBER: 0001654954-25-007785 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250707 FILED AS OF DATE: 20250707 DATE AS OF CHANGE: 20250707 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251106942 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a7036p.htm IMFINZI APPROVED IN THE EU FOR BLADDER CANCER a7036p FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of July 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________     AstraZeneca PLC   INDEX TO EXHIBITS     1. Imfinzi approved in the EU for bladder cancer   4 July 2025   Imfinzi  approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer   Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone   AstraZeneca's  Imfinzi  (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by  Imfinzi  as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).   The approval by the European Commission follows the  positive opinion  of the Committee for Medicinal Products for Human Use and is based on results from the  NIAGARA  Phase III trial, which were published in  The New England Journal of Medicine .   In a planned interim analysis, the  Imfinzi -based perioperative regimen demonstrated a statistically significant 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the  Imfinzi  arm versus 46.1 months for the comparator arm. An estimated 67.8% o